Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Prognosis of intracranial tumors

  • Age. Being young is advantageous.
  • Degree of spreading at the time of diagnosis. Absence of spreading is advantageous.
  • Degree of resection. None or minimal residual tumor after primary operation is advantageous. Degree of resection is usually dependent on the localization of the tumor.
  • Neurological function status. Normal or almost normal function is advantageous.
  • Genetic markers
    • Methylat MGMT is favorable for glioblastomas (7).
    • LOH (Loss of heterozygosity) of 1p and 19q is favorable for oligodendrogliomas (8).
    • High expression of TrkC is favorable for medullablastoma.
    • Amplification of MYCC is not favorable for medullablastoma.
    • High expression of MYCC and ERBB2 is not favorable for medullablastoma.

 Expected survival (2,6,9-15)

  Survival adults (%)
Type of tumor 1 year 5 years 10 years
Astrocytoma WHO grade II  90 %  50 %  25 %
Astrocytoma WHO grade III (anaplastic)  75 %  30 %  15 %
Astrocytoma WHO grade IV (glioblastoma)  60 % <  5 % <  2 %
Oligodendroglioma WHO grade II > 90 %  70 %  50 %
Oligodendroglioma WHO grade III (anaplastic)  85 %  40 %  25 %
Meningioma WHO grade I >95 % >90 %  90 %
Meningioma WHO grade II (atypical)  95 %  85 %  75 %
Meningioma WHO grade III (anaplastic)  85 %  50 %  25 %
CNS lymphoma  50 %  20 %  15 %
Adenoma of pituitary gland >97 %  95 %  90 %
Capillary hemagioblastoma >95 %  95 %  90 %
Brain metastasis  25 % <   5 % <   2 %

 

 

Five-year relative survival of women with malignant and non-malignant tumors in the central nervous system, in percent, during the diagnosis period 1974–2013.

Source: Cancer Registry of Norway

 

 

Five-year relative survival of men with malignant and non-malignant tumors in the central nervous system, in percent, during the diagnosis period 1974–2013.

Source: Cancer Registry of Norway

 

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2016